Welcome to our dedicated page for Allakos news (Ticker: ALLK), a resource for investors and traders seeking the latest updates and insights on Allakos stock.
The Allakos Inc. (ALLK) news page on Stock Titan aggregates company-issued updates and market-moving announcements for this clinical stage biotechnology firm. Allakos describes itself as a biotechnology company developing therapeutics that target immunomodulatory receptors on immune effector cells involved in allergy, inflammatory and proliferative diseases, with a particular focus on mast cell-driven conditions.
News items for Allakos commonly cover clinical trial milestones, such as Phase 1 single and multiple ascending dose studies of AK006 in healthy volunteers and chronic spontaneous urticaria (CSU) patients, as well as topline results from these trials. Releases have detailed safety, pharmacokinetics, pharmacodynamics, and Siglec-6 receptor occupancy data for AK006, along with exploratory efficacy outcomes in CSU.
Investors and followers can also find business updates and financial results, where Allakos reports research and development expenses, general and administrative costs, restructuring charges, cash, cash equivalents and investments, and the financial impact of halting specific development programs. These updates often include commentary on restructuring activities and cash outlook.
Another important category of news relates to strategic and corporate actions. Allakos has announced the discontinuation of AK006 development in CSU following lack of therapeutic activity in a Phase 1 cohort, significant workforce reductions, exploration of strategic alternatives, and a definitive merger agreement under which Concentra Biosciences, LLC will acquire Allakos through a tender offer and merger, subject to closing conditions.
In addition, Allakos issues scientific and conference communications, including preclinical data presentations on AK006’s mechanism of action, mast cell inhibition, and MRGPRX2-mediated mast cell activation in inflammatory skin diseases. Bookmark this page to review historical and ongoing disclosures that shape the narrative around ALLK’s clinical programs, restructuring steps, and acquisition process.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Allakos Inc. (Nasdaq: ALLK) provided a business update on March 6, 2023, reporting financial results for Q4 and full year 2022. Key developments include the initiation of a Phase 2b study of lirentelimab for chronic spontaneous urticaria and continued enrollment for atopic dermatitis. The company reported Q4 2022 research and development expenses of $35.4 million, down from $72.9 million in Q4 2021, attributed to cost-cutting measures. General and administrative expenses also decreased to $10.8 million from $23.2 million. The net loss shrank to $43.0 million from $94.4 million year-over-year, and cash reserves stood at $279.8 million.